Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HITS Chemoimmunotherapy for High-Risk Neuroblastoma
NCT03189706Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2017
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naxitamab in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Number of participants with treatment-related adverse events at 2 years and Response Rate at 2 years. Started Jun 2017; status: active, not recruiting.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03189706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189706.